OPKO Health (NASDAQ:OPK) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of OPKO Health (NASDAQ:OPK - Free Report) to a strong-buy rating in a report published on Tuesday,Zacks.com reports.

A number of other research firms have also recently weighed in on OPK. Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. Barrington Research reiterated an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a research note on Thursday, May 1st. HC Wainwright reiterated a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a research note on Monday, April 7th. Finally, JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research note on Friday, April 25th. They issued a "neutral" rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $2.75.

OPKO Health Stock Down 0.7%

OPKO Health stock traded down $0.01 during midday trading on Tuesday, hitting $1.35. 1,758,039 shares of the stock were exchanged, compared to its average volume of 3,867,082. OPKO Health has a 52-week low of $1.21 and a 52-week high of $2.04. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -19.28 and a beta of 1.34. The business's 50-day moving average price is $1.32 and its 200-day moving average price is $1.49. The company has a quick ratio of 2.28, a current ratio of 2.49 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). The company had revenue of $149.90 million during the quarter, compared to analysts' expectations of $163.13 million. OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. The firm's revenue was down 13.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.12) earnings per share. On average, research analysts expect that OPKO Health will post -0.25 EPS for the current fiscal year.

Institutional Trading of OPKO Health

Several hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC increased its holdings in OPKO Health by 68.7% during the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after acquiring an additional 373,032 shares during the period. SG Americas Securities LLC bought a new stake in OPKO Health during the 1st quarter worth approximately $585,000. Bank of America Corp DE increased its holdings in OPKO Health by 94.7% during the 4th quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company's stock worth $855,000 after acquiring an additional 282,844 shares during the period. Two Sigma Investments LP increased its holdings in OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock worth $2,422,000 after acquiring an additional 949,671 shares during the period. Finally, Norges Bank bought a new stake in OPKO Health during the 4th quarter worth approximately $1,657,000. Institutional investors own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.